Abstract
Rooibos tea (Apalathus linearis) extract, rich in glycosylated polyphenols (aspalathin and nothofagin), has been shown to improve glycaemic responses in individuals with prediabetes, a high-risk state for developing type 2 diabetes (T2D). However, evidence is scarce regarding its impact on Glucagon-like-peptide-1 (GLP-1). GLP-1 stimulates 50–70% of insulin production during a meal, also known as the incretin effect. Individuals with prediabetes may therefore benefit from an increase in GLP-1 concentration. On the other hand, a decrease in GLP-1 may indicate heightened incretin sensitivity, resulting in a reduced demand for GLP-1 secretion needed to improve glycaemic responses. We conducted an acute, single-blind, placebo-controlled, non-randomised, crossover study (GLARE study; ACTRN12617000837325) examining the impact of rooibos tea extract on GLP-1total and GLP-1active concentrations in participants with prediabetes. Nineteen participants (aged 65.0 ± 1.6 years, BMI 27.3 ± 1.1 kg/m2, and HbA1c 42 ± 1 mmol/mol) were given a placebo or rooibos tea extract on separate occasions before an oral glucose tolerance test (OGTT). Blood samples were collected at 0, 30, 60, 90 and 120 min. Data were analysed using a linear mixed model for repeated measures. Secondary analysis was conducted by stratifying participants into either a healthier or less healthy prediabetes subgroup, with the less healthy group experiencing delayed postprandial glucose and/or insulin peaks. The study outcomes demonstrated that although prior to stratification there were no significant changes in the overall total incremental area under the curve (iAUCtotal) of GLP-1total and GLP-1active in participants (p > 0.05), the healthier prediabetes subgroup exhibited a significant reduction in GLP-1active compared to the control group (479.4 vs. 1046.7 pM.min, p = 0.038, effect size Cohen’s d = 0.6). This suggests that rooibos tea extract may reduce postprandial incretin demand in people with prediabetes. More study is warranted to confirm this observation.
Author Contributions
Conceptualisation, W.X.J.L., C.S.G., P.v.H., L.C. and R.A.P.; formal analysis, W.X.J.L.; data curation, W.X.J.L., O.M.; writing—original draft preparation, W.X.J.L.; writing—review and editing, W.X.J.L., C.S.G., P.v.H., L.C. and R.A.P.; funding acquisition, W.X.J.L., C.S.G., and R.A.P. All authors have read and agreed to the published version of the manuscript.
Funding
This research was funded by the College of Health Massey University Research Funding (MURF)—RM22977.
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki, and approved by the Southern Health and Disabilities Ethics Committee (HDEC) (17/STH/82, date of approval 07 July 2017).
Informed Consent Statement
Informed consent was obtained from all participants involved in the study.
Data Availability Statement
Not applicable.
Conflicts of Interest
The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).